A study to determine the optimal puncture site for endoscopic ultrasound-guided tissue sampling in anticipation of comprehensive genomic profiling for patients suspected of having pancreatic cancer.

The Success of OncoGuide NCC OncoPanel System Analysis Criteria for Specimens Obtained by Endoscopic Ultrasound-guided Tissue Acquisition Using TopGain 19G from Primary and Metastatic Lesions in Pancreatic Cancer with Metastatic Lesions: A Prospective Self-Controlled Study - PRIMATE study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048966

Enrollment

Registered

2022-10-01

Start date

2022-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

endoscopic ultrasound-guided tissue acquisition using TopGain 19-Gauge needle

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Suspected pancreatic cancer with metastasis on CT, EUS, AUS, or MRI. Safe to perform endoscopic ultrasound-guided tissue acqusition

Exclusion criteria

Exclusion criteria: Two or more lesions in the pancreas that are suspicious for pancreatic cancer

Design outcomes

Primary

Measure	Time frame
Success rate of the NCC OncoPanel criteria for analysis in precheck of specimens obtained by endoscopic ultrasound-guided tissue acquisition from primary pancreatic lesion Success rate of the NCC OncoPanel criteria for analysis in precheck of specimens obtained by endoscopic ultrasound-guided tissue acquisition from metastatic lesions of pancreatic cancer	—

Secondary

Measure	Time frame
Success rate of the NCC OncoPanel criteria for analysis in precheck of specimens obtained by endoscopic ultrasound-guided tissue acquisition from primary pancreatic lesion and/or metastatic lesions Technical success rate of endoscopic ultrasound-guided tissue acquisition with 19-gauge needle The rate of adverse events	—

Countries

Japan

Contacts

Public ContactSusumu Hijioka

National cancer center hospital Hepatobiliary and pancreatic oncology

shijioka@ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026